MARKET

CTMX

CTMX

CytomX
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.55
+0.40
+4.91%
Closed 16:01 05/07 EDT
OPEN
8.50
PREV CLOSE
8.15
HIGH
8.93
LOW
8.32
VOLUME
663.83K
TURNOVER
--
52 WEEK HIGH
15.44
52 WEEK LOW
6.25
MARKET CAP
555.79M
P/E (TTM)
-12.0865
1D
5D
1M
3M
1Y
5Y
Mizuho Securities Releases a Buy Rating on CytomX Therapeutics (CTMX)
Mizuho Securities analyst Mara Goldstein assigned a Buy rating to CytomX Therapeutics (CTMX) yesterday and set a price target of $16.00. The company's
SmarterAnalyst · 2d ago
8-K: CytomX Therapeutics, Inc.
(EDGAR Online via COMTEX) -- false 0001501989 0001501989 2021-05-06 2021-05-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 2d ago
CytomX Therapeutics (CTMX) Reports Q1 Loss, Misses Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 10.34% and -21.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 2d ago
CytomX Therapeutics Q1 EPS $(0.26) Beats $(0.35) Estimate, Sales $15.97M Beat $15.43M Estimate
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.35) by 25.71 percent. This is a 200 percent decrease over earnings of $0.26 per share from
Benzinga · 2d ago
CytomX EPS beats by $0.06, misses on revenue
CytomX (CTMX): Q1 GAAP EPS of -$0.26 beats by $0.06.Revenue of $15.97M (-67.8% Y/Y) misses by $2.31M.Press Release
Seekingalpha · 2d ago
CytomX Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on it...
GlobeNewswire · 2d ago
CytomX Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 6, 2021 / CytomX Therapeutics, Inc. (NASDAQ:CTMX) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 5:00 PM Eastern Time.
ACCESSWIRE · 2d ago
-- Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q1 Revenue $16M
MT Newswires · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CTMX. Analyze the recent business situations of CytomX through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CTMX stock price target is 13.19 with a high estimate of 18.00 and a low estimate of 8.50.
EPS
Institutional Holdings
Institutions: 197
Institutional Holdings: 40.87M
% Owned: 62.87%
Shares Outstanding: 65.00M
TypeInstitutionsShares
Increased
43
4.17M
New
11
584.38K
Decreased
51
2.31M
Sold Out
14
1.03M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/President/Chief Executive Officer/Director
Sean McCarthy
Chief Financial Officer/Senior Vice President
Carlos Campoy
Senior Vice President
Leslie Robbins
Executive Vice President
Amy Peterson
Senior Vice President/Chief Compliance Officer/General Counsel/Secretary
Lloyd Rowland
Senior Vice President
Marcia Belvin
Senior Vice President
Nick Galli
Vice President
Jason Braun
Senior Vice President
Alison Hannah
Lead Director/Independent Director
Matthew Young
Vice President
Glenn Michelson
Director
Mani Mohindru
Independent Director
Charles Fuchs
Independent Director
Halley Gilbert
Independent Director
Frederick Gluck
Independent Director
Elaine Jones
Independent Director
James Meyers
Independent Director
John Scarlett
No Data
About CTMX
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.

Webull offers kinds of CytomX Therapeutics Inc stock information, including NASDAQ:CTMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTMX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTMX stock methods without spending real money on the virtual paper trading platform.